Amarin Pharmaceuticals will be able to promote its cholesterol drug Vascepa (icosapent ethyl) for off-label uses after resolving differences with...
Amarin Corporation had submitted a Supplemental New Drug Application (sNDA) with the FDA seeking approval for the marketing and sale...
The FDA has announced plans to hold an advisory panel review of Vascepa (icosapent ethyl) from Amarin, tentatively scheduled for...
HLS Therapeutics Inc.is pleased to announce that Health Canada has approved the use of Vascepa (icosapent ethyl) to reduce the...
Amarin Corporation plc announced that its supplemental new drug application (sNDA) for Vascepa (icosapent ethyl) capsules has been accepted for...
Amarin Corporation plc announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the FDA has voted unanimously (16-0)...
Amarin Corporation shared positive, statistically significant top-line results from Protocol Number EDPC003R01, a Phase III clinical trial of Vascepa (icosapent ethyl) conducted in China by Amarin partner, Edding.
Amarin Corporation plc presented new data from its landmark cardiovascular outcomes study of its prescription therapy, Vascepa (icosapent ethyl), the...
Amarin Corp has announced topline results from the Vascepa (icosapent ethyl) cardiovascular outcomes trial, REDUCE-IT, a global study of 8,179...